PMID- 16982544
OWN - NLM
STAT- MEDLINE
DCOM- 20070216
LR  - 20220330
IS  - 0284-186X (Print)
IS  - 0284-186X (Linking)
VI  - 45
IP  - 7
DP  - 2006
TI  - Stereotactic Body Radiation Therapy (SBRT) for lung metastases.
PG  - 808-17
AB  - The curative treatment of oligometastases with radiotherapy remains an area of 
      active investigation. We hypothesise that treating oligometastases with SBRT can 
      prolong life and potentially cure patients, while in patients with multiple lung 
      metastases SBRT can improve quality of life. Fifty patients with lung metastases 
      were treated on this study. Individuals with five or fewer total lesions were 
      treated with curative intent. Individuals with > five metastases were treated 
      palliatively. Most patients (62%) received 5 Gy/fraction for a total of 50 Gy. 
      The number of targets treated per patient ranged from one to five (mean 2.6). 
      Tumor sizes ranged from 0.3-7.7 cm in maximal diameter (median 2.1 cm). Mean 
      follow-up was 18.7 months. Local control of treated lesions was obtained in 42 of 
      49 evaluable patients (83%). Of the 125 total lesions treated, eight progressed 
      after treatment (94% crude local control). The median overall survival time from 
      time of treatment completion of the curatively treated patients was 23.4 months. 
      The progression-free survival of the same group of patients was 25% and 16% at 12 
      and 24 months, respectively. Grade 1 toxicity occurred in 35% of all the 
      patients, 6.1% had grade 2 toxicity, and 2% had grade 3 toxicity. Excellent local 
      tumor control rates with low toxicity are seen with SBRT. Median survival time 
      and progression-free survival both appear better than that achieved with standard 
      care alone. Long-term progression-free survival can be seen in a subset of 
      patients when all tumors are targeted.
FAU - Okunieff, Paul
AU  - Okunieff P
AD  - Department of Radiation Oncology, University of Rochester Medical Center, 
      Rochester, NY, USA. paul_okunieff@urmc.rochester.edu
FAU - Petersen, Anncatrine L
AU  - Petersen AL
FAU - Philip, Abraham
AU  - Philip A
FAU - Milano, Michael T
AU  - Milano MT
FAU - Katz, Alan W
AU  - Katz AW
FAU - Boros, Laszlo
AU  - Boros L
FAU - Schell, Michael C
AU  - Schell MC
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
SB  - IM
MH  - Adenocarcinoma/mortality/secondary/*surgery
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Protocols
MH  - Carcinoma, Squamous Cell/mortality/secondary/*surgery
MH  - Dose Fractionation, Radiation
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/mortality/*secondary/*surgery
MH  - Male
MH  - Middle Aged
MH  - Radiosurgery/adverse effects/*methods
MH  - Radiotherapy Dosage
MH  - Survival Analysis
MH  - Treatment Failure
MH  - Treatment Outcome
EDAT- 2006/09/20 09:00
MHDA- 2007/02/17 09:00
CRDT- 2006/09/20 09:00
PHST- 2006/09/20 09:00 [pubmed]
PHST- 2007/02/17 09:00 [medline]
PHST- 2006/09/20 09:00 [entrez]
AID - Q211N478QT611M72 [pii]
AID - 10.1080/02841860600908954 [doi]
PST - ppublish
SO  - Acta Oncol. 2006;45(7):808-17. doi: 10.1080/02841860600908954.